A recent US study raises concerns about the increasing use of CT scans in India, potentially leading to a rise in ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Dr Wouter Vogel, radiation oncologist at the Netherlands Cancer Institute, explained that the reason the glands have gone ...

"There was no way I was having that conversation with her, so I feigned stupidity and said it was outside my knowledge area." ...

Michael Hofman’s presentation at PSMA and Beyond 2025 highlighted the evolving role of the PRIMARY score in prostate cancer diagnosis. The PRIMARY study demonstrated that combining PSMA PET with MRI ...

PSMA-PET[3] imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT[4] scan) thereby ...